Risk assessment of over-the-counter cannabinoid-based cosmetics: Legal and regulatory issues governing the safety of cannabinoid-based cosmetics in the UAE
Contents
Appearance
![]() | |
Names | |
---|---|
IUPAC name
2-[2-[3-(tert-Butylamino)-2-hydroxypropoxy]phenoxy]-N-methylacetamide
| |
Identifiers | |
| |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
KEGG | |
PubChem CID
|
|
UNII |
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C16H26N2O4 | |
Molar mass | 310.394 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Cetamolol is a beta adrenergic antagonist, more specifically a β1-adrenergic blocker.[1]
Synthesis
![](https://upload.wikimedia.org/wikipedia/commons/thumb/9/9e/Cetamolol_synthesis.svg/700px-Cetamolol_synthesis.svg.png)
References
- ^ Klausner, MA; Irwin, C; Mullane, JF; Shand, DG; Leese, PT; Arnold, JD; Wollberg, W; Wagner, NB; Wagner, GS (1988). "Effect of cetamolol on epinephrine-induced hypokalemia". Journal of Clinical Pharmacology. 28 (8): 751–6. doi:10.1002/j.1552-4604.1988.tb03210.x. PMID 2905711. S2CID 30767741.
- ^ GB 1458392, "Optically-active 1-aryloxy-2,3-epoxypropane derviatives", published 1976-12-15, assigned to Imperial Chemical Industries Ltd.
- ^ BE 767781, "Alkanolamines", published 1971-11-29, assigned to Imperial Chemical Industries Ltd.
- ^ D. J. Lecount, C. J. Squire, U.S. patent 4,059,622 (1977 to ICI).